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Background: Reverse cholesterol transport is believed to be an important function of high-density lipoprotein (HDL). HDL-cholesterol from 
patients treated with the cholesteryl ester transfer protein (CETP) modulator dalcetrapib has been shown to increase cholesterol efflux in vitro in 
the absence of statin. However, in a Phase 3 trial in which almost all patients were treated with a statin, dalcetrapib failed to reduce cardiovascular 
events despite significant increases in HDL-C and apolipoprotein A1 concentrations. As a possible explanation for these disparate findings, we 
investigated the possibility that statins suppress expression of ABC transporters and thereby reduce cholesterol efflux by HDL.
methods: Potential mechanisms for a statin/cholesterol efflux interaction were investigated in vitro by measuring: 1) expression of ABCA1 and 
miR33 in human THP-1 monocytes 2) ABCA1 mRNA and cholesterol efflux in mouse J774 macrophages incubated with isolated HDL from pooled 
human plasma.
results: In THP-1 cells loaded with acetylated LDL, incubation with 1µM atorvastatin increased microRNA33 (miRNA) by 33% (P<0.05), and 
decreased ABCA1 mRNA and ABCG1 mRNA by 47% (P<0.05) and 27% (NS) respectively. In J774 mouse macrophages labeled with 3H-cholesterol, 
ABCA1 mRNA and cholesterol efflux via ABCA1 were decreased by 1µM of statins, with the following order of potency: simvastatin>pitavastatin>atorv
astatin >rosuvastatin >pravastatin; ie, the most hydrophilic statins exerted the smallest effects.
conclusions: This study suggests the possibility that statin treatment may increase miR33 expression, resulting in decreased ABCA1 expression 
and cholesterol efflux via this transporter. These findings might explain the failure of dalcetrapib to reduce cardiovascular events among patients 
treated with statins, despite an increase in HDL-C and apolipoprotein A1 concentration.
